Clinical Trial Update: Use of Bevacizumab to Modulate the Outcomes of Trabeculectomy Surgery [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating bevacizumab to modulate outcomes of trabeculectomy surgery for glaucoma was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glaucoma

Drugs mentioned

• Bevacizumab (bevacizumab)

Snippet

Sponsor: Nova Scotia Health Authority | Conditions: Glaucoma | Phase 4 | Status: WITHDRAWN